Panel Discussion | Evaluating the Evolving Treatment Landscape for IgA Nephropathy: What Happens Next as More & More Therapies Emerge?

Time: 2:45 pm
day: Pre-Conference Seminar Day

Details:

• As more approvals emerge within the IgAN landscape, how will the evolving standard of care make showing efficacy on top of these other therapies harder?
• It may require multiple therapies with distinct MOAs to optimally treat the patient with IgAN; how can industry best help enhance further knowledge about the efficacy and safety of potential combination therapeutic regimens?
• Determining which drug is best for which subset of IgAN patients: where do all the current therapies fit into the current standard of care management, and can we use observed differences in responses to match drugs to specific patient populations?
• Encouraging more effective engagement of patients in treatment and trial decision making